Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

被引：0
|
作者：
Guro F Giskeødegård
Ailin Falkmo Hansen
Helena Bertilsson
Susana Villa Gonzalez
Kåre Andre Kristiansen
Per Bruheim
Svein A Mjøs
Anders Angelsen
Tone Frost Bathen
May-Britt Tessem
机构：
[1] Norwegian University of Science and Technology (NTNU),Department of Circulation and Medical Imaging
[2] Trondheim 7491,Department of Cancer Research and Molecular Medicine
[3] Norway,Department of Urology
[4] St Olav University Hospital,Department of Chemistry
[5] Norwegian University of Science and Technology (NTNU),Department of Biotechnology
[6] NTNU,Department of Chemistry
[7] NTNU,undefined
[8] NTNU,undefined
[9] University of Bergen,undefined
来源：
British Journal of Cancer | 2015年 / 113卷
关键词：
metabolomics; serum; plasma; prostate cancer; MRS; MS; GC; acylcarnitines; glycerophospholipids; arginine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1712 / 1719
页数：7
相关论文
共 50 条
  • [1] Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
    Giskeodegard, Guro F.
    Hansen, Ailin Falkmo
    Bertilsson, Helena
    Gonzalez, Susana Villa
    Kristiansen, Kare Andre
    Bruheim, Per
    Mjos, Svein A.
    Angelsen, Anders
    Bathen, Tone Frost
    Tessem, May-Britt
    BRITISH JOURNAL OF CANCER, 2015, 113 (12) : 1712 - 1719
  • [2] Oxidative Stress in Benign Prostatic Hyperplasia and Prostate Cancer
    Pace, Gianna
    Di Massimo, Caterina
    De Amicis, Daniela
    Corbacelli, Carlo
    Di Renzo, Laura
    Vicentini, Carlo
    Miano, Lucio
    Ciancarelli, Maria Giuliana Tozzi
    UROLOGIA INTERNATIONALIS, 2010, 85 (03) : 328 - 333
  • [3] Radiotranscriptomics identified new mRNAs and miRNA markers for distinguishing prostate cancer from benign prostatic hyperplasia
    Yang, Qian
    Li, Qiuyang
    Li, Nan
    Wang, Dingyi
    Niu, Shaoxi
    Tang, Peng
    Xiao, Jing
    Zhao, Jiahang
    Wang, Pei
    Luo, Yukun
    Tang, Jie
    CANCER MEDICINE, 2023, 12 (24): : 21694 - 21708
  • [4] Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia
    Perez-Rambla, Clara
    Puchades-Carrasco, Leonor
    Garcia-Flores, Maria
    Rubio-Briones, Jose
    Antonio Lopez-Guerrero, Jose
    Pineda-Lucena, Antonio
    METABOLOMICS, 2017, 13 (05)
  • [5] Osteopontin expression in prostate cancer and benign prostatic hyperplasia
    Tozawa, K
    Yamada, Y
    Kawai, N
    Okamura, T
    Ueda, K
    Kohri, K
    UROLOGIA INTERNATIONALIS, 1999, 62 (03) : 155 - 158
  • [6] Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome
    Jan, Hammarsten
    CURRENT HYPERTENSION REVIEWS, 2006, 2 (04) : 301 - 309
  • [7] Comparative pathology of benign prostatic hyperplasia and prostate cancer
    Maini, A
    Archer, C
    Wang, CY
    Haas, GP
    IN VIVO, 1997, 11 (04): : 293 - 299
  • [8] H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia
    Zniber, Mohammed
    Lamminen, Tarja
    Taimen, Pekka
    Bostrom, Peter J.
    Huynh, Tan-Phat
    HELIYON, 2024, 10 (07)
  • [9] Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia
    Alonso, Vivian
    Neves, Adriana F.
    Marangoni, Karina
    Faria, Paula C. B.
    Freschi, Ana Paula P.
    Capaneli, Andreia C.
    Meola, Juliana
    Goulart, Luiz R.
    CANCER DETECTION AND PREVENTION, 2009, 32 (04): : 336 - 337
  • [10] Statin's role on protection from the benign prostatic hyperplasia and prostate cancer
    Hasirci, Eray
    Oguzulgen, Ibrahim
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2012, 11 (04): : 270 - 274
12345